search
Back to results

Impact of Probiotics on Weight Control and Body Composition in Overweight and Obese Individuals

Primary Purpose

Obesity

Status
Completed
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Probiotics
Placebo
Sponsored by
University of Manitoba
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Obesity

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Overweight, obese men and women volunteers aged between 18-65 yrs
  • BMI equal to or greater than 25
  • Willingness to complete questionnaires, records, and diaries associated with the study and to complete all clinic visits.
  • Willingness to discontinue consumption of fermented foods or probiotics (e.g. yoghourts, with live, active cultures or supplements), laxatives, prebiotics and any substances for control body weight.
  • Able to provide informed consent.
  • Women of childbearing potential with a negative pregnancy test at screening.

Exclusion Criteria

  • BMI greater than 35
  • Previous history of cardiovascular disease, diabetes, liver or kidney disease, inflammatory bowel disease, celiac disease, short bowel syndrome, any malabsorptive syndrome, pancreatitis, gallbladder or biliary disease.
  • Those currently taking (or have taken within the last 3 months) cholesterol-lowering, triglyceride-lowering or hypertension medications.
  • Those currently taking (or have taken within the last 3 months) lipid-lowering supplements, (e.g., omega-3 supplements, plant sterols/stanols foods and/or supplements, fibre, etc).
  • Smokers.
  • Allergic to milk, soy, or yeast (some of our probiotics strains may contains these items).
  • Use of another investigational product within 3 months of the screening visit.
  • Positive pregnancy test in women of child-bearing potential.
  • Known to be pregnant or breast-feeding or planning on becoming pregnant in the next 18 months.
  • Women of child-bearing potential not using effective contraception.
  • Use of any other treatments (medication or nutritional program) affecting body weight, food intake and/or energy expenditure.
  • Menopausal women.
  • Weight gain or loss of at least 10lbs in previous three months.
  • Uncontrolled angina within the past six months.
  • Cancer treatment (radiation, chemotherapy, surgery) within past six months or any other treatment or condition known to weaken the immune system (such as systemic corticosteroids or HIV/AIDS).
  • Any physical condition deemed likely to significantly interfere with individuals' ability to participate in a nutritional intervention.
  • Currently or at any point during the study participating in Weight Watcher's or another weight loss program or taking a medication for weight loss.
  • History of drug or alcohol (> 2 drinks daily) abuse.
  • Abnormal thyroid hormone levels.
  • Immune-compromised conditions.
  • Participant experiencing nausea, fever, vomiting, bloody diarrhoea or severe abdominal pain (past week and chronic).
  • Participants exercising > 15 miles/wk or 4,000 kcal/wk.

Sites / Locations

  • Richardson Centre for Functional Foods and Nutraceuticals

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Probiotics

Placebo

Arm Description

1 capsule per day containing probiotics

1 capsule per day without probiotics

Outcomes

Primary Outcome Measures

Body weight

Secondary Outcome Measures

Body mass index
Body fat percentage
Waist circumference
Hip circumference
Total fat mass
Total lean mass
Gut microbiome
Stool samples will be collected from participants to analyze intestinal microbiota community composition
Blood pressure
Blood total cholesterol
Blood low-density lipoprotein cholesterol
Blood high-density lipoprotein cholesterol
Blood triglycerides
Blood glucose
Blood insulin
Aspartate aminotransferase
Alanine transaminase

Full Information

First Posted
August 29, 2016
Last Updated
March 16, 2023
Sponsor
University of Manitoba
Collaborators
Lallemand Health Solutions
search

1. Study Identification

Unique Protocol Identification Number
NCT02893943
Brief Title
Impact of Probiotics on Weight Control and Body Composition in Overweight and Obese Individuals
Official Title
Impact of Probiotics on Weight Control and Body Composition in Overweight and Obese Individuals
Study Type
Interventional

2. Study Status

Record Verification Date
April 2021
Overall Recruitment Status
Completed
Study Start Date
January 1, 2017 (Actual)
Primary Completion Date
July 31, 2017 (Actual)
Study Completion Date
January 31, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Manitoba
Collaborators
Lallemand Health Solutions

4. Oversight

5. Study Description

Brief Summary
The aim of the study is to evaluate the potential of probiotics on weight management. It is hypothesized that the consumption of 1 capsule of probiotics daily will modulate the intestinal gut microbiota thereby reducing body weight and fat compared to those who do not consume probiotics. In addition, a diet supplemented with probiotics can be expected to be more beneficial than a diet without probiotic supplementation in impacting biomarkers of obesity-associated disorders including diabetes, hypertension and cardiovascular disease (CVD).
Detailed Description
Overweight, obese men and women volunteers aged between 18-65 yrs with BMI greater than or equal to 25 will be recruited from the Winnipeg (Manitoba, Canada) area to participate in a two arm crossover, randomized, double-blind, placebo-controlled, free-living intervention study for 60 days per study period following obtainment of informed consent. Participants will be informed to maintain their usual diets as well as their physical activity level. After obtaining consent, participants will be randomized to receive either 1 capsule containing probiotics, or 1 capsule of placebo daily for 60 days. Compared with the probiotic capsules, the placebo contains the same carrier material and is similar in size, shape and taste.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
30 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Probiotics
Arm Type
Active Comparator
Arm Description
1 capsule per day containing probiotics
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
1 capsule per day without probiotics
Intervention Type
Dietary Supplement
Intervention Name(s)
Probiotics
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo
Primary Outcome Measure Information:
Title
Body weight
Time Frame
60 days
Secondary Outcome Measure Information:
Title
Body mass index
Time Frame
60 days
Title
Body fat percentage
Time Frame
60 days
Title
Waist circumference
Time Frame
60 days
Title
Hip circumference
Time Frame
60 days
Title
Total fat mass
Time Frame
60 days
Title
Total lean mass
Time Frame
60 days
Title
Gut microbiome
Description
Stool samples will be collected from participants to analyze intestinal microbiota community composition
Time Frame
60 days
Title
Blood pressure
Time Frame
60 days
Title
Blood total cholesterol
Time Frame
60 days
Title
Blood low-density lipoprotein cholesterol
Time Frame
60 days
Title
Blood high-density lipoprotein cholesterol
Time Frame
60 days
Title
Blood triglycerides
Time Frame
60 days
Title
Blood glucose
Time Frame
60 days
Title
Blood insulin
Time Frame
60 days
Title
Aspartate aminotransferase
Time Frame
60 days
Title
Alanine transaminase
Time Frame
60 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Overweight, obese men and women volunteers aged between 18-65 yrs BMI equal to or greater than 25 Willingness to complete questionnaires, records, and diaries associated with the study and to complete all clinic visits. Willingness to discontinue consumption of fermented foods or probiotics (e.g. yoghourts, with live, active cultures or supplements), laxatives, prebiotics and any substances for control body weight. Able to provide informed consent. Women of childbearing potential with a negative pregnancy test at screening. Exclusion Criteria BMI greater than 35 Previous history of cardiovascular disease, diabetes, liver or kidney disease, inflammatory bowel disease, celiac disease, short bowel syndrome, any malabsorptive syndrome, pancreatitis, gallbladder or biliary disease. Those currently taking (or have taken within the last 3 months) cholesterol-lowering, triglyceride-lowering or hypertension medications. Those currently taking (or have taken within the last 3 months) lipid-lowering supplements, (e.g., omega-3 supplements, plant sterols/stanols foods and/or supplements, fibre, etc). Smokers. Allergic to milk, soy, or yeast (some of our probiotics strains may contains these items). Use of another investigational product within 3 months of the screening visit. Positive pregnancy test in women of child-bearing potential. Known to be pregnant or breast-feeding or planning on becoming pregnant in the next 18 months. Women of child-bearing potential not using effective contraception. Use of any other treatments (medication or nutritional program) affecting body weight, food intake and/or energy expenditure. Menopausal women. Weight gain or loss of at least 10lbs in previous three months. Uncontrolled angina within the past six months. Cancer treatment (radiation, chemotherapy, surgery) within past six months or any other treatment or condition known to weaken the immune system (such as systemic corticosteroids or HIV/AIDS). Any physical condition deemed likely to significantly interfere with individuals' ability to participate in a nutritional intervention. Currently or at any point during the study participating in Weight Watcher's or another weight loss program or taking a medication for weight loss. History of drug or alcohol (> 2 drinks daily) abuse. Abnormal thyroid hormone levels. Immune-compromised conditions. Participant experiencing nausea, fever, vomiting, bloody diarrhoea or severe abdominal pain (past week and chronic). Participants exercising > 15 miles/wk or 4,000 kcal/wk.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Rotimi Aluko, PhD
Organizational Affiliation
University of Manitoba
Official's Role
Principal Investigator
Facility Information:
Facility Name
Richardson Centre for Functional Foods and Nutraceuticals
City
Winnipeg
State/Province
Manitoba
ZIP/Postal Code
R3T 2N2
Country
Canada

12. IPD Sharing Statement

Learn more about this trial

Impact of Probiotics on Weight Control and Body Composition in Overweight and Obese Individuals

We'll reach out to this number within 24 hrs